GlassScriptPhysician profile
Jennifer C Fox
NPI 1225450950
$75,597.46
in general payments reported to CMS, 2019-2025
24 companies · $38K in 2025
The $38K reported for 2025 was more than what 99% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
See the full distribution for Gerontology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,423 · 2022: $2,832 · 2023: $11K · 2024: $23K · 2025: $38K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $50K · Travel and Lodging: $12K · Food and Beverage: $8,467 · Consulting Fee: $800 · Education: $204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $49,543.75 |
| Travel and Lodging | $12,328.05 |
| Food and Beverage | $8,467.08 |
| Consulting Fee | $800.00 |
| Education | $204.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $34,192.98 | 2023-2025 | Amvuttra, Onpattro |
| Actelion Pharmaceuticals US, INC. | $26,419.96 | 2021-2025 | Uptravi, Opsumit |
| E.R. Squibb & Sons, L.L.C. | $7,746.56 | 2022-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $1,572.94 | 2022-2024 | Winrevair, Verquvo |
| United Therapeutics Corporation | $1,140.32 | 2021-2025 | Tyvaso, Remodulin, Orenitram |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,049.98 | 2021-2025 | Jardiance |
| Zoll Respicardia, INC. | $668.43 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $472.74 | 2021-2025 | Wainua, Farxiga |
| Abbott Laboratories | $360.06 | 2022-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Thoratec Heartmate 3 |
| Bayer Healthcare Pharmaceuticals INC. | $318.24 | 2021-2025 | |
| Analog Devices INC. | $299.73 | 2024-2025 | Sensinel Cpm Wearable |
| Impulse Dynamics (USA) INC. | $262.32 | 2023 | Optimizer |
| Boston Scientific Corporation | $217.76 | 2021-2024 | Vigilant X4 Crt-D, Watchman Access System |
| Pfizer INC. | $168.46 | 2022-2025 | |
| Daxor Corporation | $168.36 | 2022-2023 | Bva-100 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $139.55 | 2025 | |
| Janssen Pharmaceuticals, INC | $111.57 | 2021 | |
| Sanofi-Aventis U.S. LLC | $108.14 | 2022 | |
| Amgen INC. | $55.44 | 2021-2023 | Repatha |
| Novartis Pharmaceuticals Corporation | $51.93 | 2021 | |
| Genzyme Corporation | $25.00 | 2023 | |
| Cvrx, INC. | $20.08 | 2025 | Barostim Neo System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $15.75 | 2021 | |
| Akcea Therapeutics, INC. | $11.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Fox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.